D-Dimer guided oral anticoagulation therapy for secondary prevention after venous thrombosis - D-Dimer guided OAT

Rheinische Friedrichs-Wilhelms-Universität Bonn0 个研究点目标入组 300 人开始时间: 2007年5月11日最近更新: 2022年1月17日

试验速览

暂无简介。

•To be enrolled in this study, patients must
•have an objectively confirmed first episode of unprovoced VTE or of VTE during a minor transient risk factor. Minor transient risk factors include
•- 6 weeks of estrogen therapy
•- prolonged air travel (i. e. > 6 hours)
•- pregnancy
•- less marked leg injuries or immobilization without injury or surgical intervention
•be scheduled to receive oral anticoagulant treatment for at least 3 months
•be willing to be randomized
•be willing to participate for the full duration of the study
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 180
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 120

•Exclusion criteria include
•pregnancy or breast feeding
•contraindications against OAT (i. e. intracranial hemorrhage, subarachnoid hemorrhage, hemorrhagic stroke)
•age < 18 years
•presence of antiphospholipid antibodies or any other thrombophilic risk factor requiring long-term OAT (i. e. antithrombin deficiency, hereditary PC deficiency)
•poor patient compliance

发起方

Rheinische Friedrichs-Wilhelms-Universität Bonn